Fonsie Trading House

  Why $AGPU Could Be the Sovereign AI Infrastructure Breakout of 2026 Hey traders and AI enthusiasts! If you're hunting for the next micro-cap rocket in the exploding DePIN space, buckle up—$AGPU (Axe Compute Inc.) is screaming "undervalued opportunity" right now. With a pivot from sleepy biotech to Nasdaq’s first decentralized GPU operator, this low-float beast is targeting the $400B AI cloud market head-on, and the setup is primed for liftoff. Picture this: In a world where AWS and Google leave devs waiting 40–52 weeks for GPUs, $AGPU solves the GPU crisis with instant bare-metal access via the Aethir network—cheaper, faster, and globally scalable across 200+ locations. No more virtualization overhead or egress fees; just pure performance for AI training, inference, and enterprise workloads. And with a market cap of just $23–25M against ~$343.5M in assets, investors are basically buying at a 15x discount—talk about asymmetric upside! The SCR Flywheel is genius: Stake...

  NYSE American: $ROLR – The Next Big Early-Bird Winner in iGaming?! Posted by FonsieTrader on January 08, 2026 Hey FonsieTrader community! As we kick off 2026, I'm diving deep into $ROLR (High Roller Technologies Inc), a micro-cap iGaming powerhouse that's showing all the signs of a classic turnaround play. With insider buying frenzy, revenue growth, a low float primed for squeezes, and undervalued fundamentals, this could be the early-bird winner in the exploding online gambling sector. Let's break it down with technicals (focusing on OBV, MFI, ADX as always), fundamentals, risks, and why now might be the time to load up. Buckle up – this one's got multi-bagger potential! Technical Analysis: Consolidation Loading for a Breakout Blast $ROLR's weekly chart is a textbook micro-cap setup: trapped in a multi-year descending channel since 2021 highs above $70, but now consolidating at rock-bottom levels around $2.50-$3.00 after its October 2024 IPO. This compression...

  🔬  OKYO Pharma Limited ($OKYO) – Full Due Diligence Report The Exposure Room – Fonsie Trading House Date: December 11, 2025 Price: ~$2.02 Market Cap: ~$76–80M Float: 22.47M ⭐  Executive Summary OKYO Pharma Limited (NASDAQ: OKYO) is a clinical-stage biopharmaceutical company developing first-in-class, non-opioid treatments for neuropathic corneal pain (NCP) and inflammatory eye diseases — a market with zero approved therapies and multibillion-dollar potential. With: Insiders aggressively buying, Breakthrough clinical results, Fast Track designation, Non-dilutive funding, and High-conviction analyst price targets (up to $13), $OKYO is positioning itself as one of the most asymmetric biotech setups heading into 2026. 🧬  Company Overview Founded: 2007 HQ: London, UK Sector: Healthcare – Biotechnology Employees: 4 (lean, capital-efficient structure) OKYO focuses on GPCR-targeted therapeutics, specifically topical eye-drop formulations designed to bypass systemic...